Abstract Introduction: Type 2 diabetes mellitus (T2DM) known as Mathumegam is a significant health concern in the twenty-first century. Despite great advances in contemporary science, there is a lack of moderately safe and effective drugs for treatment. The purpose of this study was to evaluate the efficacy of a poly herbal traditional decoction containing 10 herbs such as Senna auriculata (root & bark), Cissampelos pareira (root), Ficus racemosa (bark), Terminalia arjuna (bark), Acacia arabica (bark), Syzygium cumini (bark), Curcuma longa (rhizome), Terminalia chebula (fruit pulp), Phyllanthus emblica (dry fruit), and Terminalia bellirica (fruit pulp) in the management of T2DM. Materials and Methods: It was a double-blind, randomized controlled trial involving 100 T2DM patients who were not well managed by diet or exercise. For a period of 12 weeks, 50 patients in group A were administered 5g of the test medication mixed with 100ml (one tumbler) of hot water for 10 to 15 min, as well as standard Western therapy. Group B patients (n=50) received a placebo in addition to normal Western therapy. The main focus of the study was to achieve a 3-month decrease in glycosylated hemoglobin (HbA1c) levels from the starting point, with additional objectives including lowering fasting blood glucose (FBG) levels and observing changes in diabetic symptoms. Results: At the end of the trial, mean fasting blood glucose levels decreased to 119.04 ± 11.52 and 176.90 ± 13.91 mg/dL in the test and control groups, respectively. Group A showed a more significant decrease in mean fasting blood glucose levels compared to group B. This indicates that the daily use of poly herbal traditional decoction along with standard allopathic medical therapy for 3 months led to notable reductions in FBG levels. Similarly, group A showed greater improvement in the measured signs and symptoms of diabetes, such as polydipsia, polyuria, polyphagia, weariness, and burning sensation in the hands and feet compared to group B throughout the trial. At baseline, the mean HbA1c (%) in group A and group B was 7.47 ± 0.70 and 7.39 ± 0.66, respectively. After 12 weeks of investigation, the levels of glycated hemoglobin were lowered to 5.03 ± 0.53 and 6.79 ± 0.51 respectively. There were no adverse events reported during the trial period. Conclusion: This study found that the experimental medication was beneficial in T2DM, radically lowering FBG and HbA1c levels in diabetic individuals after 12 weeks of treatment.
Read full abstract